Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2017-06-22
Target enrollment:
Participant gender:
Summary
This trial is a randomised, parallel-group, multicenter phase III study for maintenance
therapy with lenalidomide in patients with multiple myeloma who were treated with high-dose
therapy and autologous stem cell transplantation as first line therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH